Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/30/2025: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -69.22% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.68M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 236444 | Beta 0.93 | 52 Weeks Range 0.71 - 3.70 | Updated Date 04/1/2025 |
52 Weeks Range 0.71 - 3.70 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.83 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.4% | Return on Equity (TTM) -128.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -708298 | Price to Sales(TTM) - |
Enterprise Value -708298 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 3271040 | Shares Floating 3223939 |
Shares Outstanding 3271040 | Shares Floating 3223939 | ||
Percent Insiders 2.12 | Percent Institutions 2.14 |
Analyst Ratings
Rating 5 | Target Price 37.75 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp (BBLG) focuses on bone regeneration technology. Founded to address unmet needs in spinal fusion, trauma, and other bone grafting procedures, it has evolved to develop and commercialize its NBCTM technology platform.
Core Business Areas
- NBCTM Technology Platform: Development and commercialization of NBCTM, a bone grafting material. It addresses bone regeneration in spinal fusion, trauma, and other orthopedic applications.
- Orthopedic Solutions: Providing solutions for bone grafting procedures.
Leadership and Structure
The leadership team consists of executives with experience in orthopedics and biotechnology. The organizational structure is typical of a small-cap biotech company.
Top Products and Market Share
Key Offerings
- NBCTM (Nellix Bone Conduction Matrix): Nellix is BBLG's core product, a bone regeneration matrix designed to improve spinal fusion outcomes. Market share data is limited for this emerging product. Competitors include Medtronic (MDT), Stryker (SYK), and NuVasive (NUVA), which hold significant market share with established bone grafting products.
Market Dynamics
Industry Overview
The bone graft substitute market is growing, driven by an aging population and increased demand for minimally invasive surgeries.
Positioning
BBLG is positioned as an innovator with its NBCTM technology, aiming to disrupt the market with improved bone regeneration. Its competitive advantage lies in the potential efficacy and safety of NBCTM.
Total Addressable Market (TAM)
The global bone graft and bone graft substitutes market is estimated at several billion dollars. BBLG is targeting a portion of this TAM with NBCTM, particularly in spinal fusion.
Upturn SWOT Analysis
Strengths
- Proprietary NBCTM technology
- Potential for improved bone regeneration
- Focus on a specific market niche
Weaknesses
- Limited commercialization experience
- Dependence on NBCTM's success
- Small market capitalization
Opportunities
- Partnerships with larger orthopedic companies
- Expansion into new applications for NBCTM
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Financial constraints
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- NuVasive (NUVA)
Competitive Landscape
BBLG faces intense competition from established orthopedic companies with significant resources and market share. Its success depends on demonstrating the superiority of NBCTM.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available.
Future Projections: Future growth depends on the commercial success of NBCTM, which is uncertain.
Recent Initiatives: Focus on clinical trials and seeking regulatory approvals for NBCTM.
Summary
Bone Biologics Corp is a high-risk, high-reward investment opportunity. Its NBCTM technology offers potential in the bone regeneration market, but it faces significant competition and financial constraints. Its success depends on clinical trial results, regulatory approvals, and successful commercialization. Investors should carefully assess the risks associated with small-cap biotech companies before investing.
Similar Companies
- MDT
- SYK
- NUVA
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be limited and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.